Ordinary acne (AV) is a chronic inflammatory disease, one of the most common skin diseases, with an incidence of 80-100%among people aged 11-30. Some in vitro studies have shown vitamin D or effective treatment of AV. However, the role of vitamin D in the development of AV and its potential treatment effects still lack evidence and require further research.
Recently, a random test published in J Dermatology Treat compared the level of AV patients and the health control group serum 25-hydroxyl vitamin D, and evaluated the relationship between the severity of the disease and the lack of vitamin D. In addition, the researchers also evaluated the impact of active supply vitamin D on serum vitamin D level, and detected their effectiveness and safety of AV management in the clinical environment.
Researchers were included in a total of 100 acne patients and 100 health control groups. They were randomly distributed to a research group with 0.25ug Afa osteosterol or a comfort group for oral placebo. The intervention time was 3 months.
The results of the analysis show that the level of serum 25-hydroxyl vitamin D of acne patients is significantly lower than that of the health control group, and its level is inversely proportional to the severity of acne. After taking antiferosol, compared with the placebo group, the level of serum 25 (OH) D of the research group was significantly improved (P <.05). In addition, compared with the placebo group, the level of serum median in the research group's patients and TNFα decreased significantly (P <.05), which was the same compared to the baseline results.
In summary
As the result, the research shows that compared to healthy people, acne patients often have a deficiency of vitamin D, so taking antiferosol orthopedly may be beneficial to the treatment of acne, and no side effects are found in the current side effects.
<!-2528: Dermatology terminal page
Primitive source:
Amal Ahmed Mohamed, et al., The impact of active vitamin D administration on the clinical outcomes of acne vulgaris. J Dermatolog Treat. 2021 Nov;32(7):756-761. doi: 10.1080/09546634.2019.1708852.